{
    "2018-10-26": [
        [
            {
                "time": "2018-10-30",
                "original_text": "Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO",
                "features": {
                    "keywords": [
                        "MRK",
                        "BMY",
                        "Q3 Earnings",
                        "Cancer Data",
                        "ESMO"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-25",
                "original_text": "What's in the Cards for Glaxo (GSK) This Earnings Season?",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "GSK",
                        "Earnings Season"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-31",
                "original_text": "Celgeneâ€™s Revlimid and Pomalyst Saw Solid Q3 Growth",
                "features": {
                    "keywords": [
                        "Celgene",
                        "Revlimid",
                        "Pomalyst",
                        "Q3 Growth"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-26",
                "original_text": "Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View",
                "features": {
                    "keywords": [
                        "Gilead",
                        "GILD",
                        "Q3 Earnings",
                        "Sales",
                        "Updates View"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-02",
                "original_text": "The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Q2",
                        "Syndax",
                        "Breast Cancer Drug",
                        "Setback",
                        "Synergy Pharma",
                        "Default"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-01",
                "original_text": "Novartis Gets EC Approval For Cosentyx Label Update In Europe - Quick Facts",
                "features": {
                    "keywords": [
                        "Novartis",
                        "EC Approval",
                        "Cosentyx",
                        "Label Update",
                        "Europe"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}